RDC 327 review rapporteur bids farewell to Anvisa this Friday (19).

The last public meeting of Anvisa's Collegiate Board in 2025, held this Wednesday (17), was marked by a special moment: the farewell of director Rômison Rodrigues Mota. He officially ends his term on December 19, leaving behind the discussion on the revision of RDC 327.

Rômison served as the rapporteur for RDC 327, the norm responsible for regulating cannabis products in Brazilian pharmacies. The topic had entered the Agency's agenda on December 10, when the director presented his favorable opinion on the draft.

However, after the reading of the vote, director Thiago Campos requested a review, halting the process. The regulatory deadline for analysis in a deliberative circuit is 30 calendar days, postponing the conclusion of the norm update.

Industry Reaction and Future Agenda

The impasse sparked reactions among industry entities. The Federal Pharmacy Council (CFF) expressed concern, advocating for the maintenance of magistral preparations within the scope of the revision of RDC 327 and warning of potential risks to patient care.

On the other hand, the Brazilian Association of Pharmaceutical Inputs Industry (ABIQUIFI) positioned itself on the suspension. The entity reinforced its confidence in Anvisa's technical work and the legitimacy of the regulatory instrument used for the review request.

Also, during the same meeting, the Agency approved the Regulatory Agenda for the 2026-2027 biennium. Two topics related to medicinal cannabis were included, including theme 9.16, which foresees the continuation of the review of RDC 327.

Tributes and Farewell

Prior to the agenda, director Leandro Safatle opened the tribute session. He highlighted Rômison's performance during challenging periods, such as the Covid-19 pandemic, emphasizing his "high professionalism and genuine commitment to the institutional mission".

In his final speech, Rômison Mota emphasized the acquired learning and the importance of balance in health regulation. "I learned that regulating is not about preventing or liberating indiscriminately. Regulating is about balancing legitimate interests, always with the population's health as the central value," he stated in a note from Anvisa.

The director thanked his colleagues and reiterated his confidence in the institution. "May this Agency continue to be a space of technical excellence, independence, and commitment to the public interest," he concluded.

Peer Recognition

The other directors also dedicated words to their colleague. Daniela Marreco recalled their 20 years of coexistence at the Agency. "Rômison never failed to assist, advise, and guide us. Congratulations on your path of firm commitment," said the director.

Thiago Campos, who requested the review of the RDC 327 process, praised his colleague's demeanor. "I found here an experienced, serene, and deeply committed director to Anvisa's institutional mission," he declared.

Finally, Daniel Pereira emphasized that the moment was not just a formal farewell. "You helped to consolidate an increasingly respected, modern, and aligned Agency with the public interest," he concluded.